360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Qiagen NV

Type: Company

Name: Qiagen NV

Nationality: Netherlands

Web Address: http://www.qiagen.com/

Fact Sheet: Fact Sheet for Qiagen NV

First reported 14 hours ago - Updated 8 hours ago - 1 reports

Eli Lilly & Company

Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliff

Eli Lilly and Company (LLY) is heading straight for a patent cliff. Zyprexa lost patent protection in most major markets in 2011. The antipsychotic's worldwide sales for Q1 2013 fell 49% year on year to $284.8 million from $562.7 in Q1 2012. Evista, which ... [Published Seeking Alpha - 14 hours ago]

Entities: Eli Lilly & Company, Erbitux, Phase III, Qiagen NV, Oncology

First reported May 22 2013 - Updated May 22 2013 - 1 reports

EXACT Sciences Corp

6 Ways You Can Profit From Molecular Diagnostics

Last week, Angelina Jolie's op-ed in the New York Times gave the field of molecular diagnostics more publicity than the industry could have wished for. If, like many investors, you are looking for a way to dial in to the trend, here is a quick look at ... [Published Seeking Alpha - May 22 2013]

Entities: Molecular Diagnostics, EXACT Sciences Corp, Myriad Genetics Inc, SEQUENOM Inc

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Qiagen NV

Potential Qiagen (QGEN) Trade Targets 10.73% Return

Qiagen NV (NASDAQ: QGEN) closed Tuesday's trading session at $18.58. In the past year, the stock has hit a 52-week low of $15.66 and 52-week high of $22.20. Qiagen (QGEN) stock has been showing support around $18.42 and resistance in the $18.80 range. ... [Published MarketIntelligenceCenter.com - May 22 2013]

Entities: Qiagen NV

First reported May 21 2013 - Updated May 21 2013 - 4 reports

Apple Inc

QIAGEN Downgraded to Strong Sell - Analyst Blog

nflx ETF DELL GOOG ETFC eeb DRI dgp ETFPY AXP dsdfs dia SPY et efii DVR AAPL DIS DKK EAT ... [Published Zecco - May 21 2013]

Entities: Qiagen NV, Apple Inc, Google Inc

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Alkermes Inc

QIAGEN Downgraded to Strong Sell Zacks

downgraded QIAGEN N.V. (QGEN) to a Zacks Rank #5 (Strong Sell) on May 16.Why the Downgrade?Earnings momentum for this molecular diagnostics company has slumped following disappointing first-quarter 2013 results. Shares of QIAGEN have been on a downtrend ... [Published Yahoo! Finance - May 21 2013]

Entities: Qiagen NV, Alkermes Inc, Illumina Inc, Molecular Diagnostics

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Peking Union Medical College

Another study backs at-home cervival cancer screening kits

More research finds that women can screen themselves for human papillomavirus (HPV) with an at-home test that is as effective as the method doctors use.Fang-Hui Zhao of Peking Union Medical College in Beijing, China and colleagues reviewed data from 13,000 ... [Published Yahoo! Singapore - May 21 2013]

Entities: Cancer, Peking Union Medical College, Acetic Acid, human papillomavirus, Qiagen NV

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Qiagen Lowered to Underperform at Zacks (QGEN)

Zacks cut shares of Qiagen (NASDAQ: QGEN) from a neutral rating to an underperform rating in a research note issued to investors on Thursday, Stock Ratings Network reports. The firm currently has $17.90 target price on the stock.Several other analysts ... [Published Mideast Time - May 20 2013]

Entities: Qiagen NV, Stocks, Robert W. Baird, ISI Group Inc

First reported May 19 2013 - Updated May 19 2013 - 1 reports

Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com

These molecular diagnostics market reports provide a comprehensive analysis for US, UK, Spain, Japan, Italy, Germany and France: Major issues pertaining to the molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, ... [Published Zecco - May 19 2013]

Entities: Molecular Diagnostics, Market, Monogram Biosciences Inc, Proteome Sciences Plc

First reported May 16 2013 - Updated May 16 2013 - 2 reports

SYGNIS licenses amplification buffer to QIAGEN

Agreement follows a global licence agreement signed with QIAGEN in 2 ... [Published MoneyAM - May 16 2013]

Entities: Qiagen NV, SYGNIS Pharma AG, Amplification

First reported May 09 2013 - Updated May 09 2013 - 2 reports

Qiagen: Limited Visibility On When Improvement Will Materialize

Home » Blogs » By ITT Investment Research:Qiagen (QGEN) is the world's leading provider of sample and assay technologies for nucleic acid purification and detection. Besides automated solutions, the company sells consumables to molecular diagnostic, academic, ... [Published BioPortfolio - May 09 2013]

Entities: Qiagen NV, Biotechnology, Molecular Diagnostics, Nucleic Acid

First reported Apr 29 2013 - Updated Apr 30 2013 - 7 reports

Qiagen Snaps Up Ingenuity for $105M

Qiagen has acquired Ingenuity Systems, provider of software solutions for the analysis and interpretation of genomic data, in a $105 million cash deal. Through this acquisition, Qiagen inherits Ingenuity’s portfolio of products derived from its Knowledge ... [Published Genetic Engineering News - Apr 30 2013]

Entities: Qiagen NV, Genomics, Peer Schatz, Ingenuity Systems Inc

First reported Apr 29 2013 - Updated Apr 30 2013 - 3 reports

Qiagen buys Ingenuity... discuss amongst yourselves.

Genetic testing specialist Qiagen NV (QGEN.DE) said it bought privately held U.S. software developer Ingenuity Systems Inc for $105 million to expand further into genetic sequencing technology.Post new commentComment: *Web page addresses and e-mail addresses ... [Published BioFind - Apr 30 2013]

Entities: Qiagen NV, Ingenuity Systems Inc, genetic testing, HTML

Quotes

Earlier this month, Eli Lilly halted development of Phase 3 candidate enzastaurin. The diffuse large B-cell lymphoma [dlbcl] drug "failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of DLBCL relapse following rituximab-based chemotherapy." Although lousy data from enzastaurin is a kick in the pants for Eli Lilly, the company still has a promising oncology pipeline...

Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliff [Published Seeking Alpha - 14 hours ago]

The abstract of the patent published by the U S Patent and Trademark Office states: "An assembly is provided that includes a tubular support core, a splice body configured to circumferentially surround the support core, a conductive shield sock comprising at least two overlapping layers and configured to circumferentially surround the splice body and a cold shrink jacket circumferentially surrounding the shield sock. The ends of the shield sock are located beneath the cold shrink jacket and the shield sock extends beyond both ends of the splice body. In some embodiments the shield sock includes folded portions that extend beyond the ends of the splice body." The patent application was filed on Feb. 2, 2010 (12/698,791). The full-text of the patent can be found at http://patft.uspto...

U.S. Patents Awarded to Inventors in Tennessee (May 24) [Published Equities.com - 17 hours ago]

Genomic Health (GHDX) describes itself as a: " focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions." Notably, it is one of the few companies in the molecular diagnostics space that has successfully advanced from losses to profits over the past five...

6 Ways You Can Profit From Molecular Diagnostics [Published Seeking Alpha - May 22 2013]

Research and Markets (http://www.researchandmarkets.com/research/rdzltq/personalized) has announced the addition of the updated "Personalized Medicine - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering...

Personalized Medicine - A Strategic Analysis of Industry Trends, Technologies, Participants and E ... [Published Individual.com - May 20 2013]

More Content

sort by: Date \| Relevance
Diabetes And Oncology Might Cushion Eli Lilly's... [Published Seeking Alpha - 14 hours ago]
U.S. Patents Awarded to Inventors in Tennessee ... [Published Equities.com - 17 hours ago]
Enforcement Report for May 22, 2013 [Published U.S. Food and Drug Administration - May 23 2013]
Personalized Medicine Market Analysis Report: 2... [Published PredictWallStreet - May 23 2013]
Molecular Diagnostics In Cancer Testing [Published TheStreet.com - May 22 2013]
6 Ways You Can Profit From Molecular Diagnostics [Published Seeking Alpha - May 22 2013]
Isothermal Nucleic Acid Amplification Technolog... [Published Individual.com - May 22 2013]
Potential Qiagen (QGEN) Trade Targets 10.73% Re... [Published MarketIntelligenceCenter.com - May 22 2013]
QIAGEN Downgraded to Strong Sell - Analyst Blog [Published Zecco - May 21 2013]
QIAGEN Downgraded to Strong Sell - Analyst Blog [Published Zecco - May 21 2013]
QIAGEN Downgraded to Strong Sell - Analyst Blog [Published Zecco - May 21 2013]
QIAGEN Downgraded to Strong Sell - Analyst Blog [Published Zecco - May 21 2013]
QIAGEN Downgraded to Strong Sell Zacks [Published Yahoo! Finance - May 21 2013]
Another study backs at-home cervival cancer scr... [Published Yahoo! Singapore - May 21 2013]
Qiagen Lowered to Underperform at Zacks (QGEN) [Published Mideast Time - May 20 2013]
Personalized Medicine - A Strategic Analysis of... [Published Individual.com - May 20 2013]
MediPoint: Predictive Breast Cancer Gene Testin... [Published SBWire - May 20 2013]
Molecular Diagnostics Market - US, UK, Spain, J... [Published Zecco - May 19 2013]
Irish Plant Scientists Conference Hosted by NUI... [Published Noodls - May 17 2013]
Analysts’ Downgrades for May, 16th (ACAT, BLK, ... [Published American Banking News - May 16 2013]
Molecular Diagnostics Market Expected to Grow a... [Published SBWire - May 16 2013]
Global Molecular Diagnostics Market 2012-2016 [Published MarketResearch.com - May 16 2013]
Qiagen (QGEN) Trading Near $18.66 Support Level [Published MarketIntelligenceCenter.com - May 16 2013]
SYGNIS licenses amplification buffer to QIAGEN [Published MoneyAM - May 16 2013]
SYGNIS licenses amplification buffer to QIAGEN [Published Individual.com - May 16 2013]
High-class steaks at the nation's innovation ce... [Published Business Spectator - May 16 2013]
Are the Bears Taking Control over QIAGEN? [Published Traders Huddle - May 16 2013]
FDA Approves Lung Cancer Diagnostic by Roche [Published IVD Technology - May 15 2013]
Global molecular diagnostics market: 11% CAGR b... [Published MyNewsDesk - May 15 2013]
HTGF Invests in Groundbreaking Innovation for P... [Published High-Tech Gründerfonds GmbH - May 15 2013]

Blogs

sort by: Date \| Relevance
Potential Qiagen (QGEN) Trade Targets 10.73% Re... [Published MarketIntelligenceCenter.com - May 22 2013] Qiagen NV (NASDAQ: QGEN) closed Tuesday's trading session at $18.58. In the past year, the stock has hit a 52-week low of $15.66 and 52-week high of $22.20. Qiagen (QGEN) stock has been showing support around $18.42 and resistance in the $18.80 range. ...
Qiagen (QGEN) Trading Near $18.66 Support Level [Published MarketIntelligenceCenter.com - May 16 2013] Qiagen NV (NASDAQ: QGEN) closed Wednesday's trading session at $18.83. In the past year, the stock has hit a 52-week low of $15.66 and 52-week high of $22.20. Qiagen (QGEN) stock has been showing support around $18.66 and resistance in the $19.10 range. ...
Next BioBeers: Friday May 31st Texcell North Am... [Published Frederick County Biotech Community - May 12 2013] It’s spring and time for the next edition of BioBeers! A new site and a new venue for spring, Texcell North America . Texcell is a CRO that specializes in viral clearance and immunoassays. Their new state of the art Viral Clearance facility open ...
Qiagen Earnings: Here’s Why Investors Don’t Lik... [Published Wall St. Cheat Sheet - Apr 29 2013] Qiagen NV ( NASDAQ:QGEN ) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 0.48%.Markets ...
Qiagen Nv Earnings Preview: Get Ahead of the An... [Published Wall St. Cheat Sheet - Apr 28 2013] Qiagen Nv ( NASDAQ:QGEN ) will report earnings after markets close on Monday, April 29th. QIAGEN N.V. provides sample and assay technologies. The Company’s technologies (in the format of consumables and automated solutions) are used to process biological ...

Press Releases

sort by: Date \| Relevance
DGAP-DD: QIAGEN N.V. english [Published GlobeNewswire: Advertising News - May 04 2013]
DGAP-DD: QIAGEN N.V. english [Published GlobeNewswire: Advertising News - May 04 2013]
DGAP-DD: QIAGEN N.V. english [Published GlobeNewswire: Advertising News - May 04 2013]
DGAP-DD: QIAGEN N.V. english [Published GlobeNewswire: Advertising News - May 04 2013]
DGAP-DD: QIAGEN N.V. english [Published GlobeNewswire: Advertising News - May 04 2013]